Chemists and chemical biologists just keep dreaming up new ways to interfere with biomolecules. That research frequently leads to promising potential medicines, and there are more and more flavors of ...
SHANGHAI, SHANGHAI, CHINA, June 11, 2026 /EINPresswire.com/ — The rapid rise of new therapeutic modalities — from peptides and oligonucleotides to targeted ...
Targeted protein degradation is changing how drug discovery teams think about disease biology. For many years, small molecule programs were built around inhibition. A compound was expected to bind a ...
Ingenix's Biological Reasoning Engine fuses biological data through Modality Fusion, a new architecture for AI in drug development. In a recent oncology engagement, the Biological Reasoning Engine ...
The discovery of a novel target can result in exceptionally successful classes of anticancer drugs. For example, the combined global sales in 2024 of PD1–PDL1 inhibitors — for which the first-in-class ...
Drug discovery is entering a new phase of complexity. From peptides and oligonucleotides to targeted protein degraders and other emerging modalities, many of today’s therapies require advanced ...
(MENAFN- EIN Presswire) EINPresswire/ -- The rapid rise of new therapeutic modalities - from peptides and oligonucleotides to targeted protein degraders (TPDs) and antibody-drug conjugates (ADCs) - is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results